Patents by Inventor Milos Simic

Milos Simic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260166147
    Abstract: This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcriptional switch (BTTS); and (b) a nucleic acid encoding an anti-inflammatory payload, wherein binding of the BTTS to a marker on the surface of a target cell activates expression of the anti-inflammatory payload by the cell. A method of reducing inflammation in the brain of a subject is also provided.
    Type: Application
    Filed: November 2, 2023
    Publication date: June 18, 2026
    Inventors: Milos SIMIC, Nishith REDDY, Wendell A. LIM
  • Publication number: 20240344025
    Abstract: Provided herein is a synthetic immuno-suppressive cell that contains comprises a molecular circuit comprising the following components: (a) a binding-triggered transcriptional switch (BTTS); and one or both of: (b) a nucleic acid encoding a pro-inflammatory cytokine sink, (c) a nucleic acid encoding an anti-inflammatory cytokine, (d) a nucleic acid encoding an immune inhibitory receptor, or ligand thereof, and (c) a nucleic acid encoding an ectonucleotidase. In this circuit, binding of the BTTS to a marker on the surface of a target cell activates expression of one or any combination of (b)-(c) by the synthetic immuno-suppressive cell.
    Type: Application
    Filed: September 21, 2022
    Publication date: October 17, 2024
    Inventors: Wendell A. LIM, Nishith REDDY, Milos SIMIC
  • Publication number: 20230055337
    Abstract: Provided herein is a cell comprising a recombinant nucleic acid encoding a transmembrane protein that has an extracellular binding domain that specifically binds to a brain-selective extracellular antigen, e.g., MOG, CDH10, PTPRZ1 or NRCAM, wherein the cell does not comprise a nucleic acid encoding an antigen-specific therapeutic that binds to a killing antigen expressed by a glioblastoma.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 23, 2023
    Inventors: Wendell A. Lim, Milos Simic, Hideho Okada, Joseph H. Choe, Payal B. Watchmaker
  • Publication number: 20220378832
    Abstract: A method for treating a subject for glioblastoma is provided. In some embodiments, the method may comprise administering to a subject a molecular circuit that includes a binding triggered transcriptional switch (BTTS) that, when bound to MOG, induces one or more encoded therapeutics specific for one or more antigens expressed by the GBM. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 1, 2022
    Inventors: Wendell A. Lim, Milos Simic, Hideho Okada, Kole T. Roybal, Joseph H. Choe, Payal B. Watchmaker